Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis

Kapata, Nathan; Grobusch, Martin P.; Chongwe, Gershom; Chanda‐Kapata, Pascalina; Ngosa, William; Tembo, Mathias; Musonda, Shebba; Katemangwe, Patrick; Bates, Matthew; Mwaba, Peter; Zumla, Alimuddin; Cobelens, Frank

doi:10.1007/s15010-017-1054-8

Cited by 13 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported in similar patient cohorts from South Africa [18,19] and Zambia [20], where the majority of patients were co-infected with HIV. However, the better treatment outcomes in the current study may be due to potential selection bias of excluding patients treated at primary health centres.…”

Section: Plos Onementioning

confidence: 58%

Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

Matambo¹,

Takarinda

Thekkur

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

Background Zimbabwe is one of the thirty countries globally with a high burden of multidrug-resistant tuberculosis (TB) or rifampicin-resistant TB (MDR/RR-TB). Since 2010, patients diagnosed with MDR/RR-TB are being treated with 20-24 months of standardized second-line drugs (SLDs). The profile, management and factors associated with unfavourable treatment outcomes of MDR/RR TB have not been systematically evaluated in Zimbabwe. Objective To assess treatment outcomes and factors associated with unfavourable outcomes among MDR/RR-TB patients registered and treated under the National Tuberculosis Programme in all the district hospitals and urban healthcare facilities in Zimbabwe between January 2010 and December 2015. Methods A cohort study using routinely collected programme data. The 'death', 'loss to follow-up' (LTFU), 'failure' and 'not evaluated' were considered as "unfavourable outcome". A generalized linear model with a log-link and binomial distribution or a Poisson distribution with robust error variances were used to assess factors associated with "unfavourable outcome". The unadjusted and adjusted relative risks were calculated as a measure of association. A pva-lue< 0.05 was considered statistically significant.

show abstract

Section: Plos Onementioning

confidence: 58%

Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

Matambo¹,

Takarinda

Thekkur

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The current study included only three patients with HIV/AIDS (Table 3). However, we are aware that HIV/AIDS contributes to poor treatment outcomes [3,13,54], and that patients taking ART have a lower risk of dying [5]. Girum et al found that HIV/AIDS positive patients with MDR-TB were three times more liable to die compared with seronegative patients [61].…”

Section: Discussionmentioning

confidence: 99%

“…The World Health Organization (WHO) believes over 10 million people globally fell ill with tuberculosis (TB) in 2017 and 2018, although the number actually reported is only 7 million [1,2]. Drug-resistant TB continues to be a global public health concern with approximately 580,000 cases worldwide and mortality worse than most cancers [1,[3][4][5][6]. Overall, TB is the leading cause of death among patients with infectious diseases [7,8].…”

Section: Introductionmentioning

confidence: 99%

Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications

Ali

Alrasheedy

Kibuule

et al. 2019

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Background: Multidrug-resistant tuberculosis (MDR-TB) has a socioeconomic impact and threatens global public health. We assessed treatment outcomes of MDR-TB and predictors of poor treatment outcomes in Sudan given current high prevalence rates. Methods: Combined retrospective and prospective cohort study at Abu-Anga hospital (TB specialized hospital in Sudan). All patients with MDR-TB between 2013 and 2017 were targeted. Results: A total of 156 patients were recruited as having good records, 117 (75%) were male, and 152 (97.4%) had pulmonary TB. Patients were followed for a median of 18 months and a total of 2108 person-months. The overall success rate was 63.5% and the mortality rate was 14.1%. Rural residency (P < 0.05) and relapsing on previous treatments (P < 0.05) were determinants of time to poor MDR-TB treatment outcomes. Conclusion: Overall, more attention needs to be given to special MDR-TB groups that are highly susceptible to poor outcomes, i.e. rural patients. As a result, it is highly recommended to maintain total coverage of medicines for all MDR-TB patients for the entire period of treatment in Sudan. It is also recommended to instigate more treatment centers in rural areas in Sudan together with programs to enhance adherence to treatments including patient counseling to improve future outcomes.

show abstract

“…Both Rifampin (RIF) and Isoniazid (INH) resistance are reliable markers of MDR-TB [9]. Drug-resistant TB remainsto be a universalpublic health concern, with nearly580,000 cases worldwide and mortality rates higher than most cancers [1,[10][11][12][13]]. WHO's surveillance data estimated 600000MDR-TBcasesand deaths of 490000 people with MDR-TB in 2016 [3].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Multidrug Resistance Mycobacterium Tuberculosis (MDR-TB) Using GeneXpert; how Serious Is the Situation?

Noor¹,

Elamin²,

Taha³

et al. 2021

Int j pharm res allied sci

View full text Add to dashboard Cite

Based on the estimation of World Health Organization (WHO), there were 558000 new cases with resistance to Rifampicin, of which 82% had Multidrug-resistant Tuberculosis (MDR-TB). We aimed to identify the outbreakof MDR-TB in River Nile state, Sudan, and the risk factors contributing to its occurrence. This descriptive crosssectional hospital-based study involved 200 specimens from patients suspected of having MDR-TB tested using an automated GeneXpert assay. Theresults of the GeneXpert assay showed that the presence of Mycobacterium tuberculosis in 81 (40.5%), and out of 81 positive test results there were 13 (16%) had MDR-TB. Additionally, 7 cases of MDR-TB were previously treated, which represented about (53%) of MDR patients. The remaining 6 MDR-TB patients were new cases and represented (47%) of MDR-TB patients. Moreover, 4 MDR-TB patients had a backgroundof contact with MDR-TB patients. Prevalence of MDR-TB in River Nile State, Sudan was 16%, which is greater than WHO estimation for Sudan (10.1%). The results revealed that the leadingrisk factor in developing MDR-TB was a backgroundof contact with MDR-TB, so adherence to treatment and social awareness about the spread of MDR-TB isa crucial preventive measure.

show abstract

Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis

Abstract: More than half of the patients diagnosed with MDR-TB were lost to follow-up before second-line treatment was initiated.

Cited by 13 publications

References 38 publications

Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications

Prevalence of Multidrug Resistance Mycobacterium Tuberculosis (MDR-TB) Using GeneXpert; how Serious Is the Situation?

Contact Info

Product

Resources

About